Literature DB >> 21470523

Tumeur myofibroblastique inflammatoire de la vessie.

Wafa Jomaa1, Sonia Ziadi, Mounir Trimeche, Faten Hammedi, Nabil Ben Sorba, Moncef Mokni, Sadok Korbi.   

Abstract

La tumeur myofibroblastique inflammatoire est une lésion classée par l'OMS parmi les néoplasies intermédiaires. Elle peut siéger dans différents organes : les poumons, le pancréas, le mésentère et l'utérus. La localisation vésicale est rare.Nous rapportons le cas d'un jeune homme de 38 ans qui a consulté pour hématurie. L'échographie a révélé la présence d'une structure tissulaire intravésicale de 3 cm de grand axe. L'examen anatomopathologique et l'étude immunohistochimique ont conclu à une tumeur myofibroblastique inflammatoire de la vessie. À partir de cette observation, nous présentons les diagnostics différentiels et les particularités anatomopathologiques de cette localisation rare.Myofibroblastic inflammatory tumor is considered as an intermediate neoplasm according to the WHO classification. It can occur in different organs: lung, pancreas, mesentery and uterus. The localization in the bladder is unusual. We report a case of a 38-year-old patient who presented with hematuria. Echography showed a 3 cm tissular structure of the bladder. Histological analysis and immunohistochemistry concluded to the diagnosis of myofibroblastic tumor of the bladder. The present work will give a general view of the myofibroblastic tumor, and will review its differential diagnosis.

Entities:  

Year:  2011        PMID: 21470523      PMCID: PMC3038354          DOI: 10.5489/cuaj.10008

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  9 in total

Review 1.  [Pseudosarcomatous myofibroblastic proliferation of the bladder].

Authors:  L Njim; A Dhouibi; Y Binous; N Touil; A Zakhama; A Moussa
Journal:  Prog Urol       Date:  2009-06-21       Impact factor: 0.915

2.  [Myofibroblastic tumor of bladder].

Authors:  I Gómez García; R Molina Burgos; E Fernández Fernández; A Palacio España; F González Chamorro; E Alvarez; S Conde Someso
Journal:  Actas Urol Esp       Date:  2005-06       Impact factor: 0.994

3.  Anaplastic lymphoma kinase expression in inflammatory pseudotumors.

Authors:  J K Chan; W Cheuk; M Shimizu
Journal:  Am J Surg Pathol       Date:  2001-06       Impact factor: 6.394

4.  Inflammatory pseudotumor: a rare cause of hematuria and shock.

Authors:  Andrea G Lantz; Nicholas E Power; Rekha Gupta; John Grantmyre
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

Review 5.  Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: a preliminary clinicopathological study of nine cases and review of the literature.

Authors:  Alex Freeman; Nicola Geddes; Philippa Munson; Jean Joseph; Pramila Ramani; Ann Sandison; Cyril Fisher; M Connie Parkinson
Journal:  Mod Pathol       Date:  2004-07       Impact factor: 7.842

Review 6.  Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?

Authors:  Liang Cheng; Stephanie R Foster; Gregory T MacLennan; Antonio Lopez-Beltran; Shaobo Zhang; Rodolfo Montironi
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

7.  Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.

Authors:  William R Sukov; John C Cheville; Austin W Carlson; Brandon M Shearer; Eli J Piatigorsky; Karen L Grogg; Thomas J Sebo; Jason P Sinnwell; Rhett P Ketterling
Journal:  Mod Pathol       Date:  2007-03-30       Impact factor: 7.842

8.  Comparison of the clinical and immunohistochemical features, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myofibroblastic tumours.

Authors:  You-Hua Jiang; Bo Cheng; Ming-Hua Ge; Ye Cheng; Gu Zhang
Journal:  J Int Med Res       Date:  2009 May-Jun       Impact factor: 1.671

Review 9.  Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential.

Authors:  Sarah Lott; Antonio Lopez-Beltran; Gregory T Maclennan; Rodolfo Montironi; Liang Cheng
Journal:  Hum Pathol       Date:  2007-06       Impact factor: 3.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.